-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, BeiGene announced that the company's core technical staff, Dr.
Ben Yong, has applied to the company for resignation in August 2021, and will no longer serve as the company's chief medical officer of immuno-oncology from February 9, 2022 (US local time).
.
Following his relocation, on the same day, Dr.
Mark C.
Lanasa will become the company's Chief Medical Officer of Immuno-Oncology
.
It is understood that although Dr.
Ben Yong will no longer serve as the company's chief medical officer of immuno-oncology, he will temporarily serve as a special consultant to the company's global R&D head to assist in the initial work of the new chief medical officer of immuno-oncology.
The smooth transition is expected to expire on June 30, 2022
.
In fact, in the context of the changing environment of the pharmaceutical industry, changes in executives of pharmaceutical companies have become very common
.
According to incomplete statistics, since 2022, at least 20 senior executives of pharmaceutical companies have changed, and many positions have changed, such as chairman, vice president, and deputy general manager
.
For example, Xingqi Eye Medicine recently announced that the company's board of directors received a written resignation report from the company's director Mr.
Liu Gaozhi on January 21, 2022.
Mr.
Liu Gaozhi applied to the company's board of directors to resign as a director for personal reasons
.
After his resignation, Mr.
Liu Gaozhi no longer holds any position in the company
.
On January 19, Zymeworks Inc.
of the United States announced its key strategic priorities and outlook for 2022, and also announced changes to its leadership team
.
Newly appointed chairman and CEO Kenneth Galbraith said 10 members of the former senior management team (or 50%, including chief people officer, chief commercial officer and chief scientific officer, etc.
) will leave the company
.
In addition, in order to cooperate with the personnel adjustment of the senior management team, staff reduction will be carried out throughout the company, and the goal is to reduce the total number of employees by at least 25% by the end of 2022.
On the 18th, Marc CROUTON, Chief Commercial Officer of Fresenius Kabi Management Committee and Asia Pacific District Executive Vice President Ulf Jasson announced a personnel appointment to employees, which will be temporarily led by Zhuang Wenyan, Executive Vice President of Fresenius Kabi China and General Manager of Fresenius Kabi Huarui Pharmaceuticals, effective February 1, 2022 Fee card business in China
.
At the same time, Fresenius Kabi has also promoted two business division heads this time.
Chen Guang, the current head of the parenteral nutrition and anesthesia division, will be promoted to the executive deputy general manager of Fresenius Kabi Huarui Pharmaceuticals.
Shen Minyue, the current head of the General Business Division, will be promoted to the general manager of Beijing Fresenius Kabi Pharmaceutical Co.
,
Ltd.
.
.
.
On the whole, many pharmaceutical companies are currently announcing personnel adjustment plans under pressure from various aspects to reduce non-core business personnel in order to save development funds
.
This is true of large pharmaceutical companies, and the same is true of small pharmaceutical companies, even more frequently in terms of personnel changes
.
The industry believes that with the further deepening of the reform of the pharmaceutical industry, the competition among enterprises will continue to intensify in the future, and the changes of senior executives of domestic and foreign pharmaceutical companies will become more frequent
.
In this context, it should be noted that with the continuous changes in the executives of pharmaceutical companies, the competition for talents may also become more intense
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Ben Yong, has applied to the company for resignation in August 2021, and will no longer serve as the company's chief medical officer of immuno-oncology from February 9, 2022 (US local time).
.
Following his relocation, on the same day, Dr.
Mark C.
Lanasa will become the company's Chief Medical Officer of Immuno-Oncology
.
It is understood that although Dr.
Ben Yong will no longer serve as the company's chief medical officer of immuno-oncology, he will temporarily serve as a special consultant to the company's global R&D head to assist in the initial work of the new chief medical officer of immuno-oncology.
The smooth transition is expected to expire on June 30, 2022
.
In fact, in the context of the changing environment of the pharmaceutical industry, changes in executives of pharmaceutical companies have become very common
.
According to incomplete statistics, since 2022, at least 20 senior executives of pharmaceutical companies have changed, and many positions have changed, such as chairman, vice president, and deputy general manager
.
For example, Xingqi Eye Medicine recently announced that the company's board of directors received a written resignation report from the company's director Mr.
Liu Gaozhi on January 21, 2022.
Mr.
Liu Gaozhi applied to the company's board of directors to resign as a director for personal reasons
.
After his resignation, Mr.
Liu Gaozhi no longer holds any position in the company
.
On January 19, Zymeworks Inc.
of the United States announced its key strategic priorities and outlook for 2022, and also announced changes to its leadership team
.
Newly appointed chairman and CEO Kenneth Galbraith said 10 members of the former senior management team (or 50%, including chief people officer, chief commercial officer and chief scientific officer, etc.
) will leave the company
.
In addition, in order to cooperate with the personnel adjustment of the senior management team, staff reduction will be carried out throughout the company, and the goal is to reduce the total number of employees by at least 25% by the end of 2022.
On the 18th, Marc CROUTON, Chief Commercial Officer of Fresenius Kabi Management Committee and Asia Pacific District Executive Vice President Ulf Jasson announced a personnel appointment to employees, which will be temporarily led by Zhuang Wenyan, Executive Vice President of Fresenius Kabi China and General Manager of Fresenius Kabi Huarui Pharmaceuticals, effective February 1, 2022 Fee card business in China
.
At the same time, Fresenius Kabi has also promoted two business division heads this time.
Chen Guang, the current head of the parenteral nutrition and anesthesia division, will be promoted to the executive deputy general manager of Fresenius Kabi Huarui Pharmaceuticals.
Shen Minyue, the current head of the General Business Division, will be promoted to the general manager of Beijing Fresenius Kabi Pharmaceutical Co.
,
Ltd.
.
.
.
On the whole, many pharmaceutical companies are currently announcing personnel adjustment plans under pressure from various aspects to reduce non-core business personnel in order to save development funds
.
This is true of large pharmaceutical companies, and the same is true of small pharmaceutical companies, even more frequently in terms of personnel changes
.
The industry believes that with the further deepening of the reform of the pharmaceutical industry, the competition among enterprises will continue to intensify in the future, and the changes of senior executives of domestic and foreign pharmaceutical companies will become more frequent
.
In this context, it should be noted that with the continuous changes in the executives of pharmaceutical companies, the competition for talents may also become more intense
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
